Cell Line Assay Kits for Drug Discovery & Development

From initial target screening to confirmatory studies to regulatory potency testing, cell line assay kits are optimized to reduce setup time, increase throughput, and deliver reproducible results — whether you are working at the bench or in a fully automated high-throughput screening (HTS) environment. If screening thousands of compounds, validating a lead series, or conducting regulatory potency testing, Eurofins DiscoverX cell line assay kits deliver the accuracy, sensitivity, and reproducibility required for high-stakes decision-making in drug discovery and development.
 

Cell line assay kits are manufactured under stringent quality control standards, ensuring reliability and reproducible results that you can trust in both basic research and regulated environments. These complete kits include two vials of stable cell line (or pool) for a specific target, along with cell culture materials, assay reagents, and detection reagent kits specific for that cell line – all conveniently packaged to ensure optimal performance in cell-based functional or binding assays across multiple applications.

The kits are designed to streamline workflows for basic research, drug discovery, and drug development by providing:

• MOA-reflective, Stable Cell Lines – Continuous culture cell lines engineered for your target’s specific MOA responses; validated for high performance and reproducibility. Stable cell lines and cell pools have been extensively validated with billions of compounds over the past 25 years, leading to numerous commercialized therapies. Each cell line has confirmed stability beyond 10 passages and is usable for a variety of research, drug discovery, and development applications.
• AssayComplete Cell Culture Reagents – Optimized reagents for preparation, maintenance, and optimal assay performance that ensure high cell viability, optimal cell morphology, and maximal assay performance with reproducible assay results
• Sensitive Detection Reagents – Application-specific detection reagents for accurate measurement of functional or binding cell-based assays, compatible with 96- to 3456-well formats and full integration with automated HTS workflows
• Standardized Protocols – To ensure consistent, reproducible results
• Comprehensive Applications – Suitable for early discovery, lead validation, MOA characterization, QC lot-release testing, late-phase drug development, and more

Stable cell lines are engineered to reflect the biological MOA for each target, enabling highly predictive in vitro models. We cover a broad spectrum of drug target classes, including:

• GPCRs
• Kinases
• Checkpoint Inhibitors
• Cytokines
• Nuclear Hormone Receptors and Epigenetic Proteins
• Transcription Factors
• And more

Eurofins DiscoverX cell line assay kits are used by leading biopharmaceutical companies worldwide to support discovery and development in diverse therapeutic programs such as:

• Oncology and Immuno-oncology – Kinases, cytokines, checkpoint inhibitors, immunomodulatory pathways, and more
• Metabolic Disease – GLP-1, GIP, glucagon, AMY, and other GPCR-based obesity and diabetes programs
• Inflammation and Autoimmune Disease – cytokine signaling, kinase modulation, and agnostic antibodies
• Cardiovascular Disease – receptor and enzyme activity modulation
• Neurological Disorders – GPCRs, ion channels, and CNS target validation

GPCR Cell Line Assays

• GPCR Products – GPCR cell-based functional assays for detecting ligand binding, second messengers, β-arrestin recruitment, and GPCR internalization and trafficking. Learn more about GPCR products.
  • β-Arrestin Recruitment Assays – Universal G-protein independent cell-based assays to quantify GPCR activation based on the recruitment of β-arrestin. Ideal for ligand bias analysis, antagonist mode screening, and studying virtually any GPCR, including orphan receptors. Learn more about β-Arrestin Assays.
  • cAMP Assays – Homogeneous cAMP detection cell-based assays to characterize ligand pharmacology and obtain reproducible performance with large assay windows and broad sensitivity ranges. Learn more about cAMP Assays.
  • Calcium Assays – Cell-based assays to measure calcium mobilization in cell lines as a direct indication of GPCR activation or inhibition. Learn more about Calcium Assays.
  • GPCR Internalization Assays – Secondary, orthogonal screening cell-based assays for measuring GPCR desensitization and recycling, as well as uncovering novel classes of compound pharmacologies and identifying safer drugs without imaging or antibodies. Learn more about GPCR Internalization Assays.
  • GPCR Pharmacotrafficking Assays – Quantitative cell-based assays to identify small molecule pharmacochaperones that act as therapeutic agents to stabilize and correct disease-relevant mutant GPCRs, ion channels, or transporters. Learn more about GPCR Pharmacotrafficking Assays.

• Kinase Products – Kinase functional and binding assays to assess kinase binding, protein turnover, and receptor activation, dimerization, phosphorylation, SH2-recruitment, and internalization. Learn more about Kinase products.
  • InCELL Target Engagement Assays – Compound-binding assays to confirm compound cell entry, measure intracellular kinase binding, screen and rank inhibitors, validate hits identified in biochemical assays, and measure cellular EC₅₀ values, all in the native cellular environment. Learn more about InCELL Target Engagement Assays.
  • Signaling Pathway Assays – Signaling pathway assays to screen for inhibitors, monitor degradation, and analyze receptor activation, phosphorylation, and downstream translocation.
  • SPRINTer^™ Targeted Protein Degradation (TPD) Assays – Detect protein turnover in screening small molecule therapeutics and quantifying changes in endogenous protein levels in disease-relevant cell models. Learn more about SPRINTer TPD Assays.
  • Receptor Tyrosine Kinase (RTK) Internalization Assays – Translocation assays of RTKs to study receptor internalization and analyze the pharmacological effects of therapeutics on this event. Learn more about Translocation Assays.

• Checkpoint Receptor Products – MOA-reflective, functional cell-based assays to analyze signaling, dimerization, internalization, and clustering/crosslinking of checkpoint receptors. Learn more about Checkpoint Receptor Products.
  • Checkpoint Receptor Signaling Assays – Assays to screen therapeutics and quantify the activation and inhibition of various signaling pathways.
  • Checkpoint Receptor Dimerization Assays – Assays to study receptor dimerization and analyze the pharmacological effects of therapeutics on this event.
  • Checkpoint Receptor Internalization Assays – Translocation assays to study receptor internalization and analyze the pharmacological effects of therapeutics on this event. Learn more about Translocation Assays.
  • Checkpoint Receptor Cytotoxicity Assays – MOA-relevant cytotoxicity assays to measure target cell death via several mechanisms of action. Learn more about Cytotoxicity Assays.

• Cytokine Receptor Products – Functional, MOA-reflective assays targeting human cytokine receptors for screening, characterization, QC lot release, and NAb studies. Learn more about Cytokine Receptor Products.
  • Cytokine Receptor Dimerization Assays – Assays to study receptor dimerization and analyze the pharmacological effects of therapeutics on this event.
  • Cytokine Receptor Functional Activity Assays – Functional assays to study receptor activity via ligand-induced SH2 domain protein recruitment.
  • Cytokine Receptor IkB Degradation Assays – Assays to measure pathway activation-induced degradation of IκB target protein.
  • Cytokine Receptor Signaling Assays – Assays for screening therapeutics and quantifying the activation and inhibition of various signaling pathways.

• Epigenetic Protein Products – Epigenetics target-based drug development products, including bromodomain and methyltransferase target engagement assays. Learn more about Epigenetic Protein Products.
• Nuclear Protein Products – Functional cell-based assays to study nuclear protein translocation to the nucleus and ligand-induced activation of nuclear hormone receptors. Learn more about Nuclear Protein Products.

• KILR^® Cytotoxicity Assays – Functional, MOA-reflective cell-based cytotoxicity assays to measure target cell death in co-cultures using a simple, non-radioactive, and dye-free method that can be easily implemented in drug discovery through QC lot release programs
• Signaling Reporter Assays – Functional, cell-based assays with a downstream read-out for screening molecules based on ligand activation or inhibition
• InCELL Target Engagement Assays – Assess compound cell entry and protein target binding, and screen and rank inhibitors, all in the native cellular environment
• SPRINTer Target Protein Degradation Assays – Quantify target protein turnover in native cellular context.
• Translocation Assays – Cell-based translocation assays for analyzing the movement of proteins (including receptor internalization) to multiple membrane compartments within the cell
• Signal Transduction Pathway Assays – Screen pathway-specific activation or inhibition
• GPCR Pharmacotrafficking Assays – Quantitative cell-based assays for the identification of pharmacochaperones that rescue misfolded membrane proteins involved in mutation diseases